Akebia Therapeutics Income Statement (2016-2025) | AKBA

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2016	Jun2016	Sep2016	Dec2016	Mar2017	Jun2017	Sep2017	Dec2017	Mar2018	Jun2018	Sep2018	Dec2018	Mar2019	Jun2019	Sep2019	Dec2019	Mar2020	Jun2020	Sep2020	Dec2020	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025
Revenue & cost
Revenue				1.53M	20.86M	28.52M	41.28M	87.32M	45.93M	48.79M	53.17M	59.85M	49.55M	71.71M	10.00M	-255.45M	88.48M	90.14M	15.00M	56.04M	52.30M	52.91M	48.76M	57.68M	41.45M	126.36M	48.71M	55.78M	40.01M	56.38M	42.05M	-128.43M	32.61M	43.65M	37.43M	46.50M	57.34M	62.47M	58.77M
Cost of Revenue												7.77M	31.26M	37.67M	38.26M	38.15M	27.71M	174.62M	30.34M	63.23M	34.61M	52.49M	15.94M	47.63M	23.11M	18.60M	38.28M	-3.43M	20.19M	17.28M	18.01M	18.66M	11.61M	17.05M	14.16M	20.36M	7.62M	9.92M	9.38M
Gross Profit												52.08M	18.30M	34.05M	-28.26M	-293.59M	60.77M	-84.47M	-15.35M	-7.20M	17.70M	0.42M	32.81M	10.05M	18.34M	107.77M	10.43M	59.21M	19.82M	39.09M	24.04M	-147.09M	21.00M	26.60M	23.27M	26.13M	49.71M	52.55M	49.38M
Operating items
Amortization - Intangibles														9.10M	9.10M	9.10M	9.10M	9.10M	6.11M	8.31M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M
Depreciation & Amortization - Total														0.40M	0.60M	0.50M		0.50M	0.50M	0.50M								0.41M	0.40M	0.40M	0.40M	0.39M	0.36M	0.40M	0.36M	0.34M	0.31M	0.32M	0.32M
Research & Development					60.05M	43.75M	58.71M	68.38M	61.40M	71.92M	70.63M	87.05M	82.35M	85.69M	74.51M	80.41M	81.23M	52.82M	46.86M	37.58M	40.61M	37.21M	40.47M	29.56M	43.83M	26.03M	28.03M	32.10M	19.69M	20.20M	13.33M	9.87M	9.73M	7.65M	8.49M	11.79M	9.75M	11.01M	14.94M
Selling, General & Administrative					5.79M	6.91M	6.75M	7.57M	9.02M	12.54M	10.38M	55.12M	34.29M	36.07M	34.18M	44.92M	37.98M	35.48M	40.17M	40.46M	41.33M	41.65M	46.36M	44.80M	44.57M	32.24M	31.89M	29.91M	25.05M	27.04M	22.71M	25.44M	25.44M	26.92M	26.52M	27.68M	25.74M	26.55M	29.09M
Restructuring Costs																										14.53M	0.18M	1.22M	0.11M	-0.09M	0.17M		0.06M
Other Operating Expenses				39.58M								0.07M	0.74M	0.49M	0.33M	0.47M	0.68M	0.54M	0.21M	0.33M	0.69M	0.89M	0.87M	1.03M	0.45M	0.89M	0.74M	0.44M	0.17M	0.55M	0.47M	0.46M	0.35M	0.36M	0.41M	0.64M	0.39M	0.58M	0.58M
Operating Expenses				39.58M	65.84M	50.66M	65.46M	75.95M	70.43M	84.45M	81.01M	142.24M	117.38M	122.66M	109.62M	126.30M	119.89M	89.34M	87.74M	78.87M	82.63M	79.76M	87.70M	75.39M	88.85M	73.69M	60.84M	64.08M	45.41M	48.09M	37.07M	36.16M	35.94M	35.33M	35.77M	40.44M	36.20M	38.46M	44.93M
Operating Income				-38.04M	-44.97M	-22.14M	-24.18M	14.61M	-24.50M	-35.66M	-27.84M	-90.16M	-75.97M	-59.52M	-55.91M	-94.89M	-59.12M	-173.82M	-58.09M	-85.40M	-64.94M	-79.34M	-54.89M	-65.34M	-59.58M	34.08M	-50.41M	-4.87M	-25.60M	-9.00M	-13.04M	1.37M	-14.94M	-8.72M	-12.51M	-14.31M	13.51M	14.09M	4.45M
EBIT				-38.04M	-44.97M	-22.14M	-24.18M	14.61M	-24.50M	-35.66M	-27.84M	-90.16M	-75.97M	-59.52M	-55.91M	-94.89M	-59.12M	-173.82M	-58.09M	-85.40M	-64.94M	-79.34M	-54.89M	-65.34M	-59.58M	34.08M	-50.41M	-4.87M	-25.60M	-9.00M	-13.04M	1.37M	-14.94M	-8.72M	-12.51M	-14.31M	13.51M	14.09M	4.45M
Non-operating items
Interest & Investment Income					0.43M	0.61M	0.84M	0.91M	1.08M	1.56M	1.78M	1.74M	0.87M	0.48M	0.23M	-0.79M	-1.97M	-2.31M	-2.27M	-2.32M	-4.80M	-4.96M	-5.08M	-5.08M	-5.06M	-5.04M	-3.95M	-1.64M	-1.56M	-1.64M	-1.41M	-1.42M	-2.50M	-2.15M	-6.66M	-6.88M	-7.77M	-6.83M	-4.75M
Other Non Operating Income					-0.01M	0.01M	0.20M		0.00M	0.03M	0.02M	0.03M	-0.08M	0.02M	-0.18M	-0.55M	0.35M	0.38M	0.41M	0.72M	0.16M	1.26M	0.43M	0.56M	1.13M	0.41M	1.17M	0.43M	0.28M	-0.01M	-0.04M	0.66M	-0.52M	-0.04M	-0.02M		0.21M	-0.03M	-0.01M
Non Operating Income				0.18M	0.43M	0.62M	1.04M	0.91M	1.08M	1.59M	1.80M	1.77M	0.79M	0.51M	0.04M	-1.34M	0.35M	0.38M	0.41M	-1.60M	0.16M	1.26M	0.43M	0.56M	1.13M	0.41M	1.17M	0.43M	0.28M	-0.01M	-0.04M	0.66M	0.10M	-0.04M	-0.02M	0.06M	0.21M	-0.03M	-0.01M
Net income details
EBT				-38.04M	-44.54M	-21.53M	-23.33M	15.52M	-23.42M	-34.07M	-26.05M	-88.39M	-75.18M	-59.02M	-55.86M	-96.23M	-60.75M	-175.75M	-59.96M	-88.38M	-69.74M	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	1.16M
Tax Provisions												-28.34M	-2.76M	-0.84M	-1.28M	-6.60M																							0.61M
Profit After Tax				-37.86M	-44.54M	-21.52M	-23.13M	15.52M	-23.42M	-34.07M	-26.05M	-60.05M	-72.42M	-58.17M	-54.59M	-94.48M	-60.75M	-175.75M	-59.96M	-87.00M	-69.58M	-83.04M	-59.54M	-69.86M	-63.51M	29.45M	-54.10M	-6.07M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M
Income from Continuing Operations				-38.04M	-44.54M	-21.53M	-23.33M	15.52M	-23.42M	-34.07M	-26.05M	-60.05M	-72.42M	-58.17M	-54.59M	-89.64M	-60.75M	-175.75M	-59.96M	-88.38M	-69.74M	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M
Consolidated Net Income				-38.04M	-44.54M	-21.53M	-23.33M	15.52M	-23.42M	-34.07M	-26.05M	-60.05M	-72.42M	-58.17M	-54.59M	-89.64M	-60.75M	-175.75M	-59.96M	-88.38M	-69.74M	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M
Income towards Parent Company				-38.04M	-44.54M	-21.53M	-23.33M	15.52M	-23.42M	-34.07M	-26.05M	-60.05M	-72.42M	-58.17M	-54.59M	-89.64M	-60.75M	-175.75M	-59.96M	-88.38M	-69.74M	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M
Net Income towards Common Stockholders				-38.04M	-44.54M	-21.53M	-23.33M	15.52M	-23.42M	-34.07M	-26.05M	-60.05M	-72.42M	-58.17M	-54.59M	-89.64M	-60.75M	-175.75M	-59.96M	-88.38M	-69.74M	-69.58M	-59.54M	-70.42M	-63.51M	29.45M	-54.10M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M
Additional items
EPS (Basic)				-0.99	-1.15	-0.53	-0.49	0.33	-0.48	-0.60	-0.46	-0.87	-0.62	-0.49	-0.46	-0.79	-0.47	-1.28	-0.42	-0.60	-0.45	-0.51	-0.34	-0.40	-0.35	0.16	-0.29	-0.04	-0.15	-0.06	-0.08	0.00	-0.09	-0.04	-0.10	-0.11	0.03	0.00	0.00
EPS (Weighted Average and Diluted)																-0.76		-0.50	-0.42	-0.60	-0.45	-0.51	-0.34	-0.40	-0.35	0.15	-0.29	-0.04	-0.15	-0.06	-0.08	0.00	-0.09	-0.04	-0.10	-0.11	0.03	0.00	0.00
Shares Outstanding (Weighted Average)	37.94M	37.98M	38.01M	38.83M	38.86M	38.86M	47.15M	47.27M	48.35M	56.88M	57.05M	57.06M	117.12M	117.86M	118.86M	129.86M	129.86M	130.27M	143.32M	144.54M	153.50M	160.12M	174.54M	174.96M	181.23M	183.53M	183.85M	183.96M	185.93M	185.93M	188.31M	188.39M	209.37M	210.29M	210.29M	218.18M	236.23M	262.64M	265.15M
Shares Outstanding (Diluted Average)																118.40M			143.31M	138.46M	153.82M	161.33M	173.78M	165.95M	179.60M	190.38M	183.88M	182.78M	184.77M	186.82M	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M	241.60M	271.10M	274.37M
EBITDA				-38.04M	-44.72M	-21.59M	-23.06M	15.30M	-23.53M	-33.98M	-26.00M	-59.91M	-72.20M	-58.11M	-54.60M	-94.49M	-60.75M	-175.76M	-59.94M	-88.38M	-69.58M	-83.04M	-59.54M	-69.86M	-63.51M	29.45M	-54.10M	-6.07M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M
Tax Rate												32.06%	3.67%	1.43%	2.29%	6.86%																							53.25%

Research Tools

Akebia Therapeutics Income Statement (2016-2025) | AKBA

Create an account

Sign In

Reset Password

Get Pro for 60% off